Charles Lynde

1. Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*
   2020/10/01 by Andreas Wollenberg, A. Wollenberg, Andrew Blauvelt +39 · 36 citations
   Medicine · Immunology and Microbiology · #Dermatology and Skin Diseases #Allergic Rhinitis and Sensitization #Psoriasis: Treatment and Pathogenesis
2. Interleukin 17A: Toward a new understanding of psoriasis pathogenesis
   2014/03/21 by Charles W. Lynde, Charles Lynde, Yves Poulin +3 · 1 citation
   Immunology and Microbiology · Medicine · #Asthma and respiratory diseases #Dermatology and Skin Diseases #Psoriasis: Treatment and Pathogenesis